Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

NXP800

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Cancer Therapeutics CRC, Nuvectis Pharma

Drug class:

Heat shock factor 1 inhibitor

Related drugs:

‹

›

AR overexpression	Cholangiocarcinoma	AR overexpression	Cholangiocarcinoma	NXP800 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) NXP800 Sensitive : D AACR 2023 - 1wk	NXP800 Sensitive: D – Preclinical AACR 2023 - 1 week NXP800 Sensitive : D AACR 2023 - 1 week - (New D)
NRAS Q61	Cholangiocarcinoma	NRAS Q61	Cholangiocarcinoma	NXP800 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) NXP800 Sensitive : D AACR 2023 - 1wk	NXP800 Sensitive: D – Preclinical AACR 2023 - 1 week NXP800 Sensitive : D AACR 2023 - 1 week - (New D)
FGFR2 overexpression	Cholangiocarcinoma	FGFR2 overexpression	Cholangiocarcinoma	NXP800 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) NXP800 Sensitive : D AACR 2023 - 1wk	NXP800 Sensitive: D – Preclinical AACR 2023 - 1 week NXP800 Sensitive : D AACR 2023 - 1 week - (New D)
FGFR1 overexpression	Cholangiocarcinoma	FGFR1 overexpression	Cholangiocarcinoma	NXP800 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) NXP800 Sensitive : D AACR 2023 - 1wk	NXP800 Sensitive: D – Preclinical AACR 2023 - 1 week NXP800 Sensitive : D AACR 2023 - 1 week - (New D)